Cite
MLA Citation
J.E. Gehin et al.. “SAT0261 Certolizumab pegol serum levels ≥20 mg/l are associated with treatment response in patients with axial spondyloarthritis. data from the nor-dmard study.” Annals of the rheumatic diseases, vol. 77, n.d., p. 994. http://access.bl.uk/ark:/81055/vdc_100144725746.0x000049